Bronchiolitis obliterans (BO) is a severe pulmonary complication of allo-SCT. This study evaluated the incidence of BO in patients undergoing allo-SCT in Hospital Universitário da Universidade Federal do Paraná, risk factors for developing this complication and prognostic factors for those patients who developed this entity. The study included 1286 patients transplanted between 1979 and 2009 who survived for 100 days or more. We diagnosed 53 cases of BO. The cumulative incidence was 2.9% in 1 year and 3.7% in 3 years. Among patients with chronic GVHD, the cumulative incidence at the same intervals was 8.4% and 9.9%, respectively. The median time between transplantation and diagnosis of BO was 260 days (49-3877 days). In the multivariate analysis the risk factors for BO were female donor, older recipients and acute GVHD. The main prognostic factor was the severity of pulmonary impairment. Patients who developed BO earlier than 260 days had a worse prognosis than those who did so later. At least 80% of deaths were directly related to BO.
INTRODUCTION
The study of late complications of SCT has acquired increasing importance owing to the increase in survival of patients submitted to this procedure. Among these complications, bronchiolitis obliterans (BO) is outstanding. It is a disease that affects the small airways, and presents high rates of morbidity and mortality. [1] [2] [3] [4] [5] [6] [7] Within the context of SCT, BO is closely related to chronic GVHD. 2, 6, [8] [9] [10] [11] The treatment of BO is still largely unsatisfactory, and in the majority of cases, stabilization of the obstructive disturbance has been considered a good result. As in any field related to chronic GVHD, the study of BO has been made difficult for a long time because of the disparity between the definitions used in the various studies. This situation began to change in 2005, when a working group of the National Institutes of Health published a proposal of consensus for the diagnosis and graduation of the severity of patients affected by chronic GVHD. 12 Since then, diverse centers have published their experience on the management of this entity, 10, 13, 14 generating a mass of data that will certainly be fundamental for the delineation of prospective studies capable of answering the innumerable questions that remain unanswered. In this study, we retrospectively analyzed 1286 allo-SCT performed in a single center to determine risk factors for BO, factors affecting survival and causes of death for patients diagnosed with BO.
MATERIALS AND METHODS Patients
From October 1979 to December 2009, 1672 patients were submitted to allo-SCT at the Hospital Universitário da Universidade Federal do Paraná, and patients with a survival ⩾ 100 days were included in the study, totalizing 1286 patients.
First, we searched the database for patients with diagnosis of BO, BO with organizing pneumonia or lung GVHD. Once these patients had been identified, we proceeded a review of their record charts, seeking to confirm or exclude the diagnosis of BO.
Follow-up of the patients
In our center, patients are seen every week in the first 100 days and then at least monthly until they complete 6 months of transplantation. Then, they are evaluated at least every 3 months until 2 years after transplantation, every 6 months until 5 years and then annually indefinitely in our center itself. Thus, our loss to follow-up was very small.
We proceeded pulmonary function tests (PFTs) 100 days, 6 months and 1 year after the transplant in all patients, irrespective of the symptomatology.
Diagnosis of BO
The diagnosis of BO was made based on the criteria suggested by the National Institutes of Health study group, adjusted to meet the retrospective nature of the study, as well as the limitations of the information available in the database. Patients considered to have BO were those who presented signs and symptoms suggestive of this entity, associated with a new obstructive ventilatory disturbance, without response to bronchodilator drugs, detected by means of the PFT performed in the absence of active pulmonary infection. We considered a suggestive clinical picture the presence of cough, dyspnea of progressive intensity and wheezing. A diagnosis of obstructive disturbance was established in the presence of both of the following factors: forced expiratory volume in 1 second (FEV1) o80% of the expected value and FEV1/forced vital capacity (FVC)o0.7 (values obtained before bronchodilator). The National Institutes of Health study group suggested the value of FEV1o 75% for diagnosis; however, they considered patients with mild BO, those with FEV1 between 60 and 79%. When it was impossible to perform the PFT, the diagnosis was based on the signs and symptoms together with tomographic findings (computed tomography became available at our center around 1990) suggestive of this entity, which are the following: evidence of air trapping, thickening of small airways and bronchiectasis.
Severity criteria
The severity of pulmonary impairment by BO was primordially based on the FEV1 measure taken in the absence of active pulmonary infection:
Mild All the variables were analyzed as categorical variables. Differences in characteristics between groups (those with BO and those without BO) were compared using Fisher's exact test. The P-values with both sides o0.05 were considered statistically significant. The variables with P o0.1 in the univariate analysis were included in multivariate Cox regression using backward elimination to assess their impact on risk for BO. We used death as a competing risk. The estimated risk of one category in relation to the reference category was reported as a relative risk, with the risk of the reference groups as the denominator.
The survival of patients with BO was compared with that of patients without BO.
Institutional review board
The study was approved by the ethics committee of the Universidade Federal do Paraná.
RESULTS

Patients submitted to SCT
Between 1979 and 2009, 1672 patients were submitted to allo-SCT at Hospital Universitário da Universidade Federal do Paraná, and of these, 1286 (76.9%) survived for the period of ⩾ 100 days (median age: 18 years; range: 0-60 years). The clinical characteristics of these patients and donors, and the indications for transplantation are described in Table 1 .
Incidence of BO after allo-SCT Fifty-three cases of BO were diagnosed, 35 in men and 28 in women (median age: 26 years, range: 2-50 years). Fifty-two were diagnosed by means of the PFT and 30 of these also had CT with alterations compatible with BO. Only one patient did not undergo the PFT and was diagnosed on the basis of signs and symptoms associated with the characteristic tomographic alterations. Seven patients had the clinical diagnosis of BO confirmed histologically.
The median follow-up time was 11.9 years (0.28-28.43 years). The median time interval between the SCT and the onset of BO was 260 days (49-3877 days), with only five cases occurring after 2 years. Of the 53 patients affected, 74% already had a diagnosis of chronic GVHD at the time of BO diagnosis. In 26% of the patients the diagnosis preceded, or was simultaneous with the appearance of other manifestations of chronic GVHD. The median time interval between the diagnosis of chronic GVHD and diagnosis of BO was 58 days (0-2737 days). Only seven patients were diagnosed after 1 year, and only two patients 2 years after the diagnosis of chronic GVHD. The temporal distribution of the diagnosis of BO may be observed in Figure 1 .
The cumulative incidence of BO among the patients was 2.9% in 1 year and 3.7% in 3 years post transplantation. Among the patients with chronic GVHD, the accumulated incidences in 1 year Where the sum of the percentages is a number o100%, this is due to the absence of such information for certain patients. Median: 18 years (0-60); interquartile range: 21 years (Q25: 9; Q75: 30). and 3 years were 8.4% and 9.9%, respectively. When we excluded patients with severe aplastic anaemia (SAA), in whom the incidence of BO was shown to be very low (0.5%), we observed an accumulated incidence in 1 and 3 years of, respectively, 3.9% and 5.1% when we considered all the patients, and 9.6% and 12.6% when we analyzed only the patients with chronic GVHD.
Risk factors for BO. We excluded patients with a diagnosis of SAA from the analysis of risk factors, because in this group of patients the incidence of BO was very low (2/389 = 0.5%). Thus, we obtained a more homogenous group for analysis. The tables with the risk factors including the patients with SAA may be seen in the Supplementary Appendices.
In the univariate analysis, we found the following risk factors: female donor, older recipients, peripheral blood as source of cells and acute GVHD (Table 2) .
Regarding age, in a subgroup analysis, we observed a higher incidence of BO in patients aged 40 years or more (9.6%) compared with those aged between 20 and 39 years (7.5%), but this difference did not reach statistical significance. In the multivariate analysis, the factors that retained statistical significance were the following: older recipients, female donor and acute GVHD (Table 3) .
According to the classification proposed by Bacigalupo et al., 15 we had only a few patients undergoing reduced-intensity conditioning, which only recently became more widely used. A large number of patients underwent a nonmyeloablative transplant, primarily patients with SAA or Fanconi anemia (note: in the latter, the definition of nonmyeloablative conditioning is especially problematic) and incidence of BO was lower in this group. Conditioning with CY 120 mg/kg and BU 12 mg/kg was used in 149 patients with SAA and only two of these developed BO; both were children. No case of BO was observed in 189 patients with SAA conditioned with CY only. Fifty-one patients with SAA received other types of conditioning.
Umbilical cord blood was used as the source of stem cells for 112 patients, of whom 90% were aged ⩽ 10 years (median: 5.5 year; 0-31 years). Three cases of BO were observed in this group.
We found no difference in the incidence or mortality of BO related to the period in which the transplant was performed.
Predictive factors of survival in patients with BO. The survival of patients affected by BO was lower compared with patients without BO (Figure 2 ). Survival in 5 years in the above-mentioned groups was 56% and 68.5%, respectively.
There was strong correlation between the severity of pulmonary impairment and survival. Of the 23 patients with BO grade 3, 19 died, against 8/15 in patients with grade 2, and no death occurred among the 15 patients with BO grade 1 (Po 0.01; Figure 3) .
Patients that developed early BO (before 260 days) presented significantly lower survival than those who did so after this time interval (Figure 4 ). There was no difference in the survival of patients diagnosed by means of PFT only (n = 22) and those in whom the diagnosis included CT (n = 30), in addition to PFT, P = 0.93.
Treatment of BO
We did not have a treatment protocol specific to BO. Patients with chronic GVHD received corticosteroids, associated or not with CsA, as a first-line treatment. The other immunosuppressive drugs have generally been used as rescue therapy, and the order of preference among them has varied over time. Of the 53 patients studied, 48 were receiving some immunosuppressive treatment when BO was diagnosed. Where the sum of the percentages is a number o100%, this is because of the absence of such information for certain patients. Abbreviations: BO = bronchiolitis obliterans; RR = relative risk.
The immunosuppressive medications used in the treatment of patients with BO were the following: corticosteroids (n = 52), CsA (n = 39), azathioprine (n = 21), thalidomide (n = 13) mycophenolate mophetyl (n = 9) and tacrolimus (n = 8).
During the course of treatment, five patients received treatment with an immunosuppressor only, 19 with two drugs, 18 with three drugs and 11 received four or more immunosuppressors.
Of the 26 survivors, 20 were already out of immunosuppressive treatment at the end of the study. Of the 27 patients who died, only 2 were not on immunosuppressive therapy.
Causes of death in patients with BO Of the 27 deaths observed during follow-up of patients with BO, 22 were directly related to progression of the GVHD, with the final event, in the majority of cases, being a fungal or bacterial pulmonary infection. Immunosuppression may have contributed to three deaths that were not shown to be directly related to BO; one case of bacterial meningitis, one case of meningococcemia and an episode of pneumonia in a patient with controlled BO. One patient committed suicide 12 years after the SCT and one patient died after recurrence of ALL.
DISCUSSION
The retrospective nature of the study and the fact that it comprises a period of 30 years have led to some limitations, among those we may mention variation in the availability of diagnostic methods over the course of time; dependence on a database not specifically designed for this study; absence of a uniform definition of BO, which could lead to underdiagnosis and the absence of an established treatment protocol.
In this study, we reported 53 cases of BO. Some cases of less severity, without important symptomatology and characterized by only a mild obstructive disturbance, may not have been reported because they were not recognized by the assistant doctors. This hypothesis is supported by the study of Au et al., 10 which showed that among 63 patients who met criteria for BO, 11 had not been recognized as such by the staff who accompanied them. Nevertheless, we believe that the large majority of cases were identified, and the incidence we found was similar to those reported in the main studies, 7, 10, 13, 14 particularly in those that used the diagnostic criteria suggested by the National Institutes of Health.
It is important to highlight a few characteristics of our sample that differ from many of the previously published series: we had more than 50% of patients with nonmalignant diseases, half of the patients were aged ⩽ 18 years, bone marrow was the source of cells in almost 90% of patients and 80% of transplants were performed using related donors.
We opted for the exclusion of patients with a diagnosis of SAA from the analysis of risk factors because in this group of patients the incidence of BO was much lower than in all the others. Thus, we obtained a more homogenous group for analysis.
In our study, the risk factors identified in the multivariate analysis were the following: female donor, older patients and acute GVHD.
The female donor is a very well-known risk factor for chronic GVHD. However, its association with BO has only been described by one researcher. 7 Older patients presented a higher incidence of BO, especially those aged ⩾ 20 years. Dudek et al. 6 have reported the higher incidence of BO in older patients and found only one case of BO among 269 transplanted patients aged between 0 and 9 years. It is possible that underdiagnosis could be, at least, partly responsible for this difference. The PFT is only reliable from the age of 5 years, 16 and performing thorax tomography in this age group presents technical difficulties. Nevertheless, a physiopathological explanation should not be discarded. The only study that specifically approached the pediatric population, without specifying an age limit for inclusion, showed an incidence of 8.3% in 216 patients, with a median age of 10 years. 17 Acute GVHD is another very well-known risk factor for chronic GVHD, and has also been described as a risk factor for BO. 6, 7 Peripheral blood as a source of cells has been described as an important risk factor for BO. 7 In our sample, peripheral blood did not attain statistical significance in the multivariate analysis as a risk factor for BO, probably as a result of the small number of patients who used this source of cells.
The patients with Fanconi anemia were the only ones who developed BO after being conditioned with CY alone. The failure of the DNA repair mechanisms presented by these patients and the consequently greater tissue damage presented is the most probable explanation for the fact. This low incidence of BO among patients undergoing nonmyeloablative transplant reinforces the thesis that the intensity of the conditioning is an important risk factor for the development of BO.
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The present study confirmed that the patients who develop early BO presents a lower probability of survival, which has also been demonstrated by other authors. 6, 11, 14 These patients, as we understand it, should be the priority focus of studies that evolve new approaches to treatment.
The response to treatments was not analyzed owing to the wide heterogeneity of the therapies used, which prevented any attempt to perform statistical analysis. However, an individualized analysis of the patients (not presented) allowed us to perceive that, as Curtis et al. 18 had already observed, once a moderate or severe obstructive disturbance was established, the chance of significant improvement of the patient, with the therapeutic arsenal available, is remote and in this group mortality attained 70%, with death having occurred as a result of complications directly related to BO in almost all the cases.
The median time interval between the SCT and diagnosis of BO found by us was lower than that reported in the main studies. 6, 7, 10, 11, 13, 14 We observed that 13 patients were diagnosed in the first 150 days after transplantation, and 2 even before 100 days had elapsed. It is possible that earlier diagnosis resulted from the fact that we recommended the performance of PFTs 100 days, 6 months and 1 year after the transplant in all patients, irrespective of the symptomatology, a procedure that is not followed by all services. Irrespective of the cause, the existence of cases diagnosed before or a little after the 100th day after transplantation, in addition to cases of BO diagnosed concomitantly with the first manifestations of chronic GVHD in other organs, or even in the absence of these, alerts to the need for strict observation of the pulmonary symptoms and raises the question with respect to the convenience of earlier tracing by means of PFT, even in asymptomatic patients.
